Licaminlimab not checked

Oculis · OCS-02

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.”In the company’s words, NCT07548632 on ClinicalTrials.gov
Tested for
Dry Eye Disease (DED)
Main trialPhase 2/3
“The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.”In the company’s words, NCT07548632 on ClinicalTrials.gov
Other names
OCS-02

Other drugs for Dry Eye Disease (DED)

All 44 drugs for Dry Eye Disease (DED)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2/3Active, not recruiting Dec 2026 A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
Phase 2Completed 27 Mar 2024 Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Licaminlimab

Following is part of Solo: you see every change to Licaminlimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in